Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1Breast 1

Conditions

Uveal Melanoma 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Breast Neoplasms 1Adrenocortical Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 3Trastuzumab 3Sunitinib 3Magnetic Resonance Spectroscopy 3selpercatinib 2palbociclib 2lenvatinib 2larotrectinib 2belinostat 2Surveys and Questionnaires 2Specimen Handling 2Sirolimus 2Nivolumab 2Immunoglobulin G 2Fluorodeoxyglucose F18 2Disulfides 2Biopsy 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1tipifarnib 1temsirolimus 1spartalizumab 1sapanisertib 1romidepsin 1relatlimab 1regorafenib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Interleukin-13 × Breast × Clear all
NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Stanford University

Phase 1 Recruiting
18 enrolled
BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡